论文部分内容阅读
目的探讨肺表面活性物质(PS)用药预防及治疗早产儿呼吸窘迫综合征(RDS)的可行性。方法我院胎龄≤34周的早产儿23例,于生后预防应用PS(预防组);同期确诊为RDS38例应用呼吸机和PS(治疗组),比例两组RDS发生率及病死率。结果预防组RDS发生2例,发生率为⒏7%,低于我院同期收治的≤34周早产儿RDS发生率3⒐4%;治疗组RDS的死亡率为⒎8%,低于同期收治的早产儿RDS的病死率4⒊1%。结论PS预防用药可降低早产儿RDS发生率,在治疗早产儿RDS方面有显著效果,降低死亡率。
Objective To investigate the feasibility of pulmonary surfactant (PS) for prevention and treatment of respiratory distress syndrome (RDS) in premature infants. Methods Twenty-three preterm infants with gestational age≤34weeks were enrolled in this study. PS (prophylaxis group) was used in the prevention and treatment after birth. In the same period, 38 cases were treated with ventilator and PS (treatment group). The incidence of RDS and mortality were compared between the two groups. Results The incidence of RDS was 27% in the prevention group, which was lower than 3⒐4% of the premature infants with ≤34 weeks admitted in our hospital. The RDS mortality rate in the treatment group was ⒎8%, lower than that of the RDS The mortality rate 4 ⒊ 1%. Conclusions PS prophylaxis can reduce the incidence of RDS in preterm infants and have a significant effect in treating premature infants with RDS and reduce mortality.